Versant Venture Management LLC Takes Position in Tempest Therapeutics, Inc. (NASDAQ:TPST)

Versant Venture Management LLC bought a new position in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the fourth quarter, HoldingsChannel reports. The firm bought 3,507,055 shares of the company’s stock, valued at approximately $2,927,000. Tempest Therapeutics accounts for approximately 3.4% of Versant Venture Management LLC’s holdings, making the stock its 6th biggest position. Versant Venture Management LLC owned 0.08% of Tempest Therapeutics as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Virtu Financial LLC bought a new stake in Tempest Therapeutics during the 4th quarter worth approximately $36,000. Geode Capital Management LLC boosted its position in shares of Tempest Therapeutics by 42.7% during the third quarter. Geode Capital Management LLC now owns 220,067 shares of the company’s stock valued at $308,000 after buying an additional 65,826 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in Tempest Therapeutics during the third quarter worth $34,000. Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Trading Down 0.2 %

Shares of NASDAQ:TPST opened at $0.82 on Wednesday. The stock has a market cap of $35.93 million, a PE ratio of -0.54 and a beta of -1.83. The stock’s fifty day simple moving average is $0.87 and its two-hundred day simple moving average is $0.99. Tempest Therapeutics, Inc. has a 1-year low of $0.70 and a 1-year high of $6.00.

About Tempest Therapeutics

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.